Research Article
Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal
Table 4
Characteristics of patients developing tubercular pleural effusion (n=2).
| | Patient 1 | Patient 2 |
| Age in years | 23 | 29 |
| Disease duration in months | 96 | 22 |
| HLA B27 | Positive | Positive |
| TST at baseline | Negative | Negative |
| IGRA at baseline | Negative | Negative |
| ASDAS CRP at baseline | 2.97 | 4.15 |
| CXR | Right sided pleural effusion | Right sided pleural effusion |
| HRCT chest | Rt sided pleural effusion with mediastinal lymph node | |
| CRP mg/L | 120 | 29.0 |
| AFB | Not seen | Not seen |
| Pleural fluid | | |
| TC per cumm | 2960 | 4389 |
| DC % | N 17, L 80 | N 9, L 91 |
| Protein gm% | 5.7 | 4.9 |
| Glucose mg% | 79 | 56 |
| ADA U/L | 31.4 | 62.3 |
| LDH | 523 | 324 |
| Culture | No growth | No growth |
| Adalimumab dose | dose (6 months gap) | (4 months gap) |
|
|